A r t i c l e s Most evidence suggests that primitive and definitive hematopoiesis in the mouse and human develop from distinct progenitors that are specified at different sites and times in the early embryo (reviewed in ref. 1) . Primitive hematopoiesis is thought to derive from a multipotent progenitor called the hemangioblast, which is characterized by co-expression of the receptor tyrosine kinase KDR (also known as FLK1 or VEGFR2) and the primitive streak transcription factor brachyury, and by its ability to generate both vascular and hematopoietic progeny 2 . This program rapidly transitions through a specialized population of endothelial cells with hemogenic potential, known as hemogenic endothelium 3 . In contrast, definitive hematopoiesis is best defined by development from hemogenic endothelium that is specified at different sites throughout the embryonic vasculature (reviewed in refs. 1, 4) .
Studies with mouse and human embryonic stem cells (hESCs) have provided compelling evidence that hematopoietic development in differentiation cultures recapitulates key stages of embryonic hematopoiesis 5, 6 . In both models, the onset of the primitive hematopoietic program is marked by upregulation of the KDR receptor and the development of hemangioblasts 7, 8 , followed by a transient wave of primitive hematopoiesis that gives rise to a limited spectrum of lineages, including primitive erythroid, macrophage and megakaryocyte (reviewed in ref. 9 ). Definitive hematopoiesis, as measured by T-lymphoid potential, emerges after the establishment of the primitive hematopoietic program and develops from a progenitor population that displays characteristics of hemogenic endothelium [10] [11] [12] . Analyses of the signaling pathways that regulate the development of the two hPSC-derived human hematopoietic programs revealed that they differ in their requirement for activin-nodal signaling at the early stages of differentiation. Whereas specification of primitive hematopoiesis is temporally dependent on the activin-nodal pathway, definitive hematopoietic development is not 12 . These observations suggest that primitive and definitive hematopoiesis are specified early within hPSC differentiation cultures and raise the possibility that, with appropriate markers, it might be possible to physically separate the progenitors of these two programs during the stage of activinnodal dependence.
RESULTS

CD235a is expressed on primitive hematopoietic progenitors
To identify surface antigens that define primitive and definitive progenitors, we screened hESC-derived mesoderm populations at different stages on an anti-CD antibody array containing ~370 known antibodies 13 (http://www.ocigc.ca/antibody/). From this screen, glycophorin A (CD235a) was the only antigen to show an interesting pattern as it was expressed on a subpopulation of cells within embryoid bodies during early mesoderm differentiation (data not shown). This was an unexpected finding as glycophorin A is considered to be an erythroid-specific antigen. It is, however, in line with the observation that this marker is expressed on hPSC-derived CD34 + cells 14 , suggesting that it is likely to be present on nonerythroid cells early in human development.
To determine whether CD235a marks cells with hematopoietic potential at this early time, we analyzed its expression and that of KDR on embryoid body populations of different stages generated from H1 hESCs using our previously described step-wise, serum-free Wnt signaling controls the specification of definitive and primitive hematopoiesis from human pluripotent stem cells
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Efforts to derive hematopoietic stem cells (HSCs) from human pluripotent stem cells (hPSCs) are complicated by the fact that embryonic hematopoiesis consists of two programs, primitive and definitive, that differ in developmental potential. As only definitive hematopoiesis generates HSCs, understanding how this program develops is essential for being able to produce this cell population in vitro. Here we show that both hematopoietic programs transition through hemogenic endothelial intermediates and develop from KDR + CD34 − CD144 − progenitors that are distinguished by CD235a expression. Generation of primitive progenitors (KDR + CD235a + ) depends on stage-specific activin-nodal signaling and inhibition of the Wnt-b-catenin pathway, whereas specification of definitive progenitors (KDR + CD235a − ) requires Wnt-b-catenin signaling during this same time frame. Together, these findings establish simple selective differentiation strategies for the generation of primitive or definitive hematopoietic progenitors by Wnt-b-catenin manipulation, and in doing so provide access to enriched populations for future studies on hPSC-derived hematopoietic development.
A r t i c l e s approach 12 ( Fig. 1a) . Kinetic analyses revealed that CD235a was first expressed at day 3 of differentiation on a subset of KDR + mesoderm, 24 h after the emergence of the T + (also known as T brachyury) primitive streak-like population ( Fig. 1b-d) . At this stage, the mesodermal cells do not express CD34 or CD144, markers found on hemogenic endothelium, hematopoietic or endothelial lineage cells (reviewed in refs. 4, 15) . Its co-expression with KDR at day 3 suggests that CD235a marks a subpopulation of hematopoietic mesoderm, possibly fated to the primitive lineage. To investigate this possibility, we analyzed the expression of CD235a after manipulation of the activin-nodal signaling pathway, given that it is required for primitive hematopoietic development 12, 16 . Inhibition of activin-nodal signaling by addition of the small-molecule antagonist SB-431542 (SB) between days 2 and 3 of differentiation prevented the development of the KDR + CD235a + population (Fig. 1e) . In contrast, activation of the pathway by the addition of activin A during the same period of time led to an increase in its size. These changes in response to manipulation of the activinnodal pathway support the hypothesis that expression of CD235a marks primitive hematopoietic progenitors.
To formally test this hypothesis, we next isolated the KDR + CD235a + and KDR + CD235a − fractions from day 3 activin-induced embryoid bodies and the KDR + CD235a − fraction from day 3 SB-treated embryoid bodies (Fig. 1e,f) and assayed them for hemangioblasts as a first measure of primitive hematopoietic potential. The activin A-derived KDR + CD235a + population contained a tenfold higher frequency of hemangioblasts than the corresponding KDR + CD235a − population ( Fig. 1g) . No hemangioblasts were detected in the KDR − CD235a − fraction (data not shown) or in the SB-treated KDR + CD235a − fraction ( Fig. 1g) . These results demonstrate that CD235a is expressed on the hemangioblast and confirms that its expression marks an early stage of primitive hematopoietic development.
To further characterize the potential of the different KDR + mesoderm populations, we isolated them by fluorescence-activated cell sorting (FACS), aggregated the cells and cultured the aggregates (as in Fig. 1f ) for up to 6 d (total of 9 d of culture) to replicate the time frame used in our previous study to identify primitive and definitive hematopoiesis in hPSC-derived populations 12 . The derivative populations were analyzed for different cell surface markers, including CD34 to monitor the emergence of hemogenic endothelium or hemogenic endothelial progenitors 14 , CD235a as a measure of primitive hematopoietic potential and CD43 as an indication of hematopoietic specification. CD43 is a hematopoietic-specific marker that is expressed on progenitors of both the primitive and definitive lineages 12, 14, 17 . All three KDR + progenitors gave rise to CD34 + cells within 1 d of culture, likely reflecting specification of the hematopoietic and vascular lineages. The KDR + CD235 + mesoderm generated the largest CD34 + population and the only one that co-expressed CD235a (Fig. 1h; top 
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A r t i c l e s culture, the proportion of CD34 + cells declined in all three populations. At this stage, the majority (>70%) of the cells in the KDR + CD235 + mesoderm-derived population expressed CD43, indicative of hematopoietic commitment. In contrast, fewer than 20% of the cells in the populations derived from the CD235a − progenitors were CD43 + . The CD43 + population generated from the KDR + CD235a + progenitors likely represents the expansion of the primitive hematopoietic program.
To test this, we next assayed the day 6 reaggregation cultures for the presence of primitive erythroid progenitors (also known as colonyforming cells; EryP-CFCs) which, in methylcellulose, will give rise to small colonies of primitive erythroblasts that express the embryonic form of globin, HBE (reviewed in refs. 9, 18) . Colony assays revealed that the KDR + CD235a + mesoderm-derived aggregates contained a significantly higher (P = 0.001) frequency of EryP-CFCs than those generated from either the activin A-induced or SB-treated KDR + CD235a − mesoderm ( Fig. 1i) . Taken together with the hemangioblast and flow cytometric analyses, these findings demonstrate that the earliest identified progenitor of the human primitive hematopoietic program is marked by the co-expression of KDR and CD235a.
CD235a separates primitive and definitive hematopoietic mesoderm
In addition to the CD43 + cells, both the KDR + CD235a + and KDR + CD235a − progenitors gave rise to a distinct CD34 + CD43 − population by day 9 of culture ( Fig. 1h) . This was of interest, as until recently, this cell surface expression pattern was associated only with hPSC-derived progenitors of the definitive hematopoietic program 12 . Given this, we assayed these populations for T-lymphoid and erythroid progenitors to assess their hematopoietic potential (as in Fig. 1f ). For the erythroid analyses, CD34 + CD43 − populations generated following the reaggregation of either day 3 CD235a + or CD235a − cells were isolated by FACS and co-cultured with OP9-DL1 stromal cells for 7 d, as we have shown that this co-culture step is necessary to promote the development of erythroid progenitors from the embryoid body-derived CD34 + CD43 − population 12 . Following co-culture, the cells were harvested and assayed for colony-forming potential in methylcellulose. Notably, both CD34 + CD43 − populations generated similar numbers of medium-to large-sized, burst-like erythroid colonies ( Fig. 2a,b ) that were morphologically distinct from the smaller EryP-CFCderived colonies ( Figs. 1i and 2b) . Analyses of the embryonic (HBE1) and fetal (HBG1,2) globin gene expression patterns (reviewed in ref. 18 ) in these erythroid colonies suggested that the CD34 + CD43 − progenitors they were generated from were different. The burst-like large colonies obtained from the CD34 + CD43 − population derived from the KDR + CD235a − mesoderm expressed significantly higher (P = 0.002) levels of globins associated with definitive hematopoiesis, including HBG1,2 (Fig. 2c , i) and HBA1,2 (data not shown) than the colonies generated from the KDR + CD235a + mesoderm-derived CD34 + CD43 − cells (as in Fig. 1i ). Comparison of the ratios of the levels of HBG1,2 to HBE1 
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A r t i c l e s revealed that the cells in the KDR + CD235a + mesoderm-derived colonies expressed more embryonic than fetal globin and in this regard were similar to the EryP-CFC-derived colonies. Roughly equal levels of HBG1,2 and HBE1 were detected in the large colonies generated from the KDR + CD235a − mesoderm-derived CD34 + CD43 − progenitors ( Fig. 2c, ii) . These patterns indicate that the large colonies obtained from the CD34 + CD43 − population generated from the KDR + CD235a + mesoderm contain primitive erythroblasts and develop from a progenitor that arises late in the culture after the emergence of the EryP-CFCs. As lymphoid potential is a distinguishing feature of definitive hematopoiesis 1 , we next analyzed each of the two aggregate-derived CD34 + CD43 − populations for T-lymphoid and natural killer (NK) cell potential using the OP9-DL4 co-culture assay 12, 19 . Both CD34 + populations efficiently gave rise to a CD56 + CD11b low population, indicating that both possess NK cell potential (Fig. 2d) . In striking contrast, T cell potential was restricted to the KDR + CD235a − mesoderm-derived CD34 + CD43 − population ( Fig. 2e) . Taken together with the above erythroid analyses, these results provide strong evidence that the KDR + CD235a − and KDR + CD235a + mesoderm-derived CD34 + populations contain progenitors of definitive and primitive hematopoiesis, respectively.
Both programs transition through CD34 + hemogenic endothelium Further characterization of the respective day 6 CD34 + CD43 − populations revealed that both express the set of surface markers (CD144, KDR and CD117, but not CD45; Fig. 2f ) and transcription factors (RUNX1, GATA2, SCL and LMO2; Fig. 2g ) commonly used to identify hemogenic endothelium (reviewed in refs. 4, 15) . When plated under appropriate conditions in vitro, hemogenic endothelium undergoes an endothelial-to-hematopoietic transition that can be measured by the emergence of round cells that express the pan-hematopoietic marker CD45 (ref. 14) . Both CD34 + CD43 − populations gave rise to adherent monolayers within 3 d of hemogenic endothelium culture, and by day 7, nonadherent CD45 + populations were readily detected (Fig. 2h,i) . Collectively, these observations demonstrate that both the KDR + CD235a − and KDR + CD235a + progenitors transition through a CD34 + CD43 − hemogenic endothelium stage that cannot be distinguished based on the markers currently used to identify this population 15 .
Wnt-b-catenin signaling regulates specification of either program
Next we investigated the role of specific signaling pathways in regulating primitive and definitive hematopoiesis with the goal of identifying strategies to promote one program or the other. We previously demonstrated that activin-nodal signaling is required for specification of primitive hematopoiesis and that stage-specific inhibition of this pathway generates populations enriched in definitive progenitors 12 . However, modulation of this pathway did not negatively affect definitive hematopoietic development, indicating that other factors may regulate this program. In the initial studies, we chose to investigate 
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A r t i c l e s Wnt-β-catenin given its role in the regulation of hematopoiesis in the mouse ESC differentiation model [20] [21] [22] [23] . For these analyses, we focused on the mesoderm specification stage (days 2-3) immediately following T induction (Fig. 1a) . Inhibition of the pathway by the addition of the small-molecule IWP2 (ref. 24 ) led to a twofold increase in the size of the CD235a + population compared to the DMSO-treated control.
In contrast, addition of the GSK-3 inhibitor CHIR99021 (CHIR), a Wnt agonist 25 , during the same time frame inhibited development of the CD235a + population (Fig. 3a,b) . The effect of Wnt-β-catenin signaling on the emergence of the KDR + CD235a + population was observed with two hESC lines (H1 and HES2) and one human induced pluripotent stem cell (hiPSC) line (MSC-iPS1; Fig. 3b ), suggesting that it is a conserved mechanism for human hematopoietic specification. Analyses of hemangioblast potential showed that the IWP2treated KDR + CD235a + fraction was enriched for these progenitors, indicating that under these conditions, as in the unmanipulated cultures, CD235a expression marks the onset of primitive hematopoiesis (Fig. 3c) . When isolated and cultured as aggregates, the three different KDR + progenitors gave rise to CD34 + cells within 24 h of culture ( Fig. 3d) . As expected, only the IWP2-treated KDR + CD235a + progenitors generated a CD34 + CD235a + population. At day 6 of aggregate culture, more than 90% of the IWP2-treated KDR + CD235a + mesoderm-derived population and almost 40% of the corresponding KDR + CD235a − mesoderm-derived population expressed CD43 (Fig. 3e) . Very few CD43 + cells were detected in the culture generated from the CHIR-treated KDR + CD235a − progenitors (Fig. 3e) , suggesting that CHIR treatment, similar to SB treatment (Fig. 1i) , inhibited primitive hematopoiesis. Primitive erythroid potential (EryP-CFC) correlated with the proportion of CD43 + cells and was found to be highly enriched in the population generated from the IWP2-derived KDR + CD235a + progenitors (Fig. 3f) , indicating that inhibition of Wnt did not affect primitive hematopoiesis. Although Wnt-β-catenin inhibition did not alter the balance of primitive hematopoiesis between the KDR + CD235a + and KDR + CD235a − mesoderm-derived populations, it did affect their definitive hematopoietic potential. As expected, the KDR + CD235a + mesoderm-derived CD34 + CD43 − progenitors lacked T cell potential, as demonstrated by the absence of CD45 + cells in the co-culture (Fig. 3e; bottom row) . Surprisingly, when Wnt-β-catenin was inhibited between days 2 and 3, the KDR + CD235a − mesoderm-derived CD34 + CD43 − population was also devoid of T cell potential, suggesting that early inhibition of Wnt signaling blocks definitive hematopoietic development. Analyses of the other fractions (CD34 +/− CD43 + ) generated following IWP2 treatment also failed to uncover any T cell potential (data not shown), ruling out the possibility that inhibition of Wnt signaling induced a change in the surface marker phenotype of the definitive hematopoietic progenitors. T-lymphoid potential was detected in the CD34 + CD43 − population generated from KDR + CD235a − mesoderm treated with CHIR ( Fig. 3e) . Taken together, these findings indicate that Wnt-β-catenin signaling at early stages of development plays a pivotal role in the generation of the two human hematopoietic programs, as it inhibits primitive hematopoiesis but appears to be required for specification of definitive hematopoiesis.
qRT-PCR analyses of the Wnt reporter target gene AXIN2 (ref. 26 ) revealed a strong upregulation of expression after CHIR treatment, and repression after IWP2 treatment (Fig. 3g) , indicating that these small molecules are regulating canonical Wnt activity. Inhibition of activin-nodal signaling with SB-431542 also led to an increase in AXIN2 expression compared to the DMSO control ( Fig. 3g) , suggesting that endogenous activin-nodal signaling may be affecting canonical Wnt activity. A relationship between the pathways is also supported by the observation that manipulation of both affects specification of the primitive and definitive hematopoietic programs. Western blot analyses revealed that nuclear β-catenin levels in the activin A-or IWP2-treated day 3 embryoid bodies were significantly lower (P < 0.05) than those in the SB-or CHIR-treated cultures, further demonstrating that the Wnt-β-catenin pathway is downregulated during primitive hematopoietic specification with activin-nodal signaling (Fig. 3h,i) . Manipulation of the Wnt pathway did not affect SMAD2 phosphorylation levels (data not shown).
Our analyses of the day 3 populations (Fig. 3b) showed that the effect of Wnt signaling on the development of the CD235a + population was observed in different hPSC lines, including an hiPSC line, . Given the application of iPSC technology to disease modeling and future cell therapy, we were interested in determining whether early-stage Wnt signaling would also affect definitive hematopoietic development from this iPSC line. In the absence of any manipulation of the Wnt-β-catenin pathway, we expected that the KDR + CD235a − mesoderm-derived CD34 + CD43 − population would display T cell potential. This was not the case, however, as neither this population nor the primitive KDR + CD235a + mesoderm-derived population contained (a) Schematic for undisrupted embryoid body differentiation. hPSC were differentiated following Wnt activation or inhibition between days 2 and 3 and then VEGF and cytokine supplementation until day 9, as in Figure 1a . (b) Colony-forming progenitor potential of day 9 populations, as in a. n ≥ 5; mean ± s.e.m. Student's t-test, relative to DMSO treatment *P ≤ 0.05, **P ≤ 0.01. (c) Representative CD34 and CD43 expression on day 9 populations, as in a. (d) CD34 + CD43 − cells, as in a, were analyzed for T cell potential after 28 + d OP9-DL4 co-culture. (e) Summary of hematopoietic potential following Wnt manipulation between days 2 and 3 of differentiation. CHIR99021 treatment prevents the development of the primitive hematopoietic program while specifying the definitive program, whereas IWP2 prevents the specification of the definitive hematopoietic program while promoting the primitive hematopoietic program. Wnt or nodal manipulation npg A r t i c l e s T cell progenitors ( Fig. 3j; left panel) . Given our observations that definitive hematopoietic specification is Wnt dependent, we speculated that these findings may be indicative of suboptimal levels of endogenous Wnt signaling in the hiPSC-derived mesoderm. Indeed, western blot analyses revealed lower levels of nuclear β-catenin in day 3 hiPSCderived embryoid bodies than in embryoid bodies generated from H1 (Fig. 3h,k) . Addition of CHIR to the hiPSC cultures between days 2 and 3 of differentiation reduced the size of the CD235a population ( Fig. 3b,j; right panel) and promoted the definitive hematopoietic fate as demonstrated by presence of T cell progenitors in the CD34 + CD43 − population (Fig. 3j) . These observations show that the lack of T cell potential was due to suboptimal endogenous Wnt-β-catenin signaling in the day 2-3 population and that it is possible to 'rescue' definitive potential by activating the pathway during this time. Taken together, these findings further support the interpretation that specification of definitive hematopoiesis in hPSCs depends on stage-specific activation of the Wnt-β-catenin pathway. To determine whether it is possible to direct primitive and definitive hematopoietic fates in the differentiation cultures without isolating the three KDR + progenitors, we cultured the CHIR-or IWP2-treated (days 2-3) embryoid bodies, as in Figure 1a , until day 9 and then assayed the entire population for EryP-CFC or the FACS-isolated CD34 + CD43 − populations for T cell potential (Fig. 4a) . The cultures treated with either SB-431542 or CHIR99021 contained no CD43 + cells or EryP-CFC, indicating that these manipulations inhibited primitive hematopoiesis in the context of whole embryoid bodies (Fig. 4b,c) . In contrast, IWP2 treatment led to an increase in the size of the CD43 + population and the frequency of EryP-CFC in the differentiation cultures, demonstrating that inhibition of the Wnt-βcatenin pathway promotes primitive hematopoiesis in the embryoid bodies. The opposite patterns were observed for T cell potential as the CD34 + CD43 − population from the SB-and CHIR-treated embryoid bodies contained T-lymphoid progenitors whereas the IWP2-treated population did not (Fig. 4d) . These findings demonstrate that through the simple stage-specific manipulation of the Wnt-β-catenin pathway in embryoid bodies, it is possible to generate either primitive or definitive hematopoietic progenitors (Fig. 4e) .
DISCUSSION
The ability to produce HSCs from hPSCs will require methods for efficient specification of definitive hematopoietic progenitors. Here we investigated the earliest stage of hematopoietic commitment in vitro and gained the following insights that now enable us to derive populations consisting of either primitive or definitive progenitors. First, we found that expression of CD235a at day 3 of differentiation marks the KDR + mesoderm fated to the primitive hematopoietic lineage and distinguishes it from the KDR + CD235a − mesoderm that gives rise to definitive hematopoiesis. Second, we showed that specification of the definitive program depends on Wnt-β-catenin signaling and that stage-specific manipulation of this pathway promotes definitive hematopoiesis while inhibiting primitive hematopoiesis. Third, we demonstrated that both programs transit through a hemogenic endothelial intermediate that undergoes an endothelial-tohematopoietic transition and gives rise to CD45 + hematopoietic cells.
Together, these findings support a model ( Fig. 5 ) of human hematopoietic development in which the primitive hematopoietic program, defined by the emergence of KDR + CD235a + mesoderm, is specified by the combination of activin-nodal signaling and inhibition of the Wnt-β-catenin pathway, whereas specification of definitive KDR + CD235a − mesoderm is dependent on Wnt-β-catenin signaling. Within 24 h of differentiation, both mesoderm populations give rise to CD34 + cells that may represent the earliest stage of commitment to hemogenic endothelium. Following 6 d of culture (total of 9 d), the KDR + CD235a + mesoderm generates a large CD43 + population that represents the emergence and expansion of primitive hematopoiesis, as demonstrated by the presence of EryP-CFC. Although we identified CD34 + CD43 − hemogenic endothelium in these reaggregation cultures after 6 d, it was clearly specified much earlier, likely within 24 h with the emergence of the CD34 + population, as EryP-CFC are present by day 6. In this model, primitive hemogenic endothelium would generate hematopoietic progeny over a period of several days, possibly generating different progenitors at different times. Hematopoietic commitment of the CHIR-treated KDR + CD235a − mesoderm did not occur in the 6-day aggregate cultures as indicated by the low number of CD43 + cells and lack of hematopoietic progenitors ( Fig. 3e,f) . Hematopoietic potential was only revealed after culture of the day 6 CD34 + cells in hemogenic endothelial conditions (Fig. 2h,i) or with Notch ligand expressing stromal cells (OP9-DL1 or OP9DL-4; Fig. 2a,d,e) , indicating that specification of these definitive progenitors may be Notch dependent, an interpretation consistent with previous studies showing that definitive hematopoietic development is dependent on Notch signaling (reviewed in ref. 28 Figure 5 Model of primitive and definitive hematopoietic specification from hPSCs. After formation of a primitive streak-like population, KDR + CD235a + mesoderm fated to the primitive hematopoietic lineage is specified by the combination of activin-nodal signaling and Wnt inhibition, whereas activation of the Wnt-β-catenin pathway specifies KDR + CD235a − -definitive mesoderm. The KDR + CD235a + mesoderm gives rise to a rapid burst of primitive hematopoiesis, marked by the emergence of a CD43 + population and the development of EryP-CFCs by day 6 of culture (9 d total) . In contrast, the KDR + CD235a − mesoderm does not generate hematopoietic progeny during this time frame. Following 6 d of culture, both mesodermal populations give rise to CD34 + CD43 − cells that express common markers of hemogenic endothelium and display multilineage hematopoietic potential. However, only the KDR + CD235a − mesoderm-derived CD34 + CD43 − population shows T-lymphoid potential. npg A r t i c l e s not earlier-stage CD34 + definitive populations would display similar potential remains to be determined.
Hematopoietic development in various model organisms is typically thought to occur in distinct, successive 'waves' (reviewed in ref. 1) . The observations that the primitive KDR + CD235a + mesoderm and the definitive KDR + CD235a − mesoderm are specified at the same time within 72 h of the onset of differentiation are not consistent with an exclusively temporal model of human hematopoietic development. Rather, they are more in line with findings from Runx1-Cre lineage tracing studies in the mouse that demonstrated HSC contribution from yolk sac progenitors specified as early as embryonic stage E7.5, a stage overlapping with the emergence of the primitive hematopoietic program 29, 30 . The ability to separate the primitive and definitive hematopoietic lineages at the KDR + mesoderm stage of development has enabled us to monitor the progression of these two programs and demonstrate that they both transition through hemogenic endothelium intermediates that can be distinguished only on the basis of T-lymphoid potential, as both generate erythroid, myeloid (data not shown) and NK lineage cells, and both display surface marker phenotypes and gene expression patterns currently used to define hemogenic endothelium. The observation that both KDR + progenitors generated cells with an NK phenotype provides evidence for the existence of distinct primitive and definitive NK cells, a concept supported by previous studies 31, 32 . The erythroid colonies generated from the two populations expressed different ratios of HBE1 and HBG1,2 globin, suggesting that the colony-forming cells they derived from represented different stages of human erythroid development. Although the expression pattern of the KDR + CD235a + mesoderm-derived colonies is indicative of primitive erythroblasts, the pattern of the colonies generated from the KDR + CD235a − mesoderm is not consistent with the next stage of erythroid development, the fetal stage, as they retain high levels of HBE1. Although unexpected, this pattern may be indicative of a transition stage in human embryonic and fetal erythropoiesis as colonies generated from human 6-week-old fetal liver also co-express HBE1 and HBG1,2 globin 33 . The lack of markers to distinguish the primitive and definitive CD34 + CD43 − populations demonstrates that the identification of a hemogenic endothelium population without documentation of T-lymphoid potential can no longer be used as an indication of definitive hematopoiesis. It also raises the distinct possibility that hemogenic endothelium populations isolated from hPSC-differentiation cultures on the basis of existing markers such as CD34, CD144 and CD45 are mixtures of primitive and definitive hematopoietic cells.
The findings that Wnt-β-catenin signaling inhibits primitive hematopoiesis are consistent with recent observations that activation of the pathway at early stages in hPSC differentiation cultures led to a reduction in hemangioblast potential and inhibition of primitive erythroid potential, respectively 34, 35 . This effect of Wntβ-catenin signaling in the human system appears to be opposite to that described in the mouse ESC model, in which activation of the pathway during early mesoderm specification is required for establishment of the primitive program 22 . However, these differences may reflect subtle differences in the stage at which the populations were analyzed, as Liu et al. 36 recently demonstrated that transient Wnt inhibition via Er71 expression is required for specification of murine primitive hemangiogenic mesoderm at a stage comparable to that evaluated in our study in the human cultures. In addition to a role at the early mesoderm specification stage, several recent studies have demonstrated that Wnt signaling functions at the level of HSC development in the aorta-gonad-mesonephros region of the developing mouse embryo. We found that inhibition of the Wnt-β-catenin pathway by retinoic acid signaling was necessary for HSC development from hemogenic endothelium 37 , whereas the study of Ruiz-Herguido et al. 38 provided evidence that Wnt signaling was required at a stage before HSC specification, possibly at the level of hemogenic endothelium development. Together, these observations establish a role for Wnt signaling at multiple stages of definitive hematopoietic development, ranging from induction of the program to specification and/or maturation of the HSC.
Endogenous levels of Wnt-β-catenin signaling in some hPSC lines such as H1 hESCs appear to be sufficient for specification of the definitive hematopoietic program, whereas in others they may be too low to establish this fate. Given the variability of endogenous Wnt signaling across different hPSCs lines 39 , these findings highlight the importance of establishing appropriate levels of Wnt-β-catenin signaling during the mesoderm specification step for generating the definitive hematopoietic program. Through stage-specific manipulation of the Wnt-β-catenin pathway, it is now possible to routinely generate hPSC-derived populations containing definitive but not primitive hematopoietic progenitors. Attempts to repopulate recipient animals with enriched hPSC-derived CD34 + definitive progenitors have not yet been successful, suggesting that these cells may represent pre-HSCs that require additional maturation signals to engraft an animal. Progenitors with T cell potential have been identified in the mouse embryo at stages before the emergence of HSCs 40, 41 . Although the origin of these T-lymphoid cells has not yet been established, it is possible they derive from progenitors comparable to the hPSC-derived CD34 + hemogenic endothelium and similarly require additional signals to mature. hPSC-derived definitive hematopoietic progenitors, generated through the strategy described in this study, represent ideal targets for defining the pathways that regulate the generation of HSCs from the CD34 + hemogenic endothelium stage cells.
METHODS
Methods and any associated references are available in the online version of the paper.
